Lacidipine
Title: Lacidipine
CAS Registry Number: 103890-78-4
CAS Name: (E)-4-[2-[3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester
Additional Names: diethyl (E)-4-[2-[2-(tert-butoxycarbonyl)vinyl]phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-[o-[(E)-2-carboxyvinyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 4-tert-butyl diethyl ester
Manufacturers' Codes: GR-43659X; GX-1048
Trademarks: Caldine (Boehringer, Ing.); Lacimen (Menarini); Lacipil (GSK); Lacirex (Guidotti); Midotens (Boehringer, Ing.); Motens (Boehringer, Ing.)
Molecular Formula: C26H33NO6
Molecular Weight: 455.54
Percent Composition: C 68.55%, H 7.30%, N 3.07%, O 21.07%
Literature References: Dihydropyridine calcium channel blocker. Prepn: C. Semeraro et al., DE 3529997; eidem, US 4801599 (1986, 1989 both to Glaxo). Clinical pharmacology: M. Safar et al., Clin. Pharmacol. Ther. 46, 94 (1989). HPTLC determn in urine: V. R. Kharat et al., J. Pharm. Biomed. Anal. 28, 789 (2002). Clinical trial in atherosclerosis: A. Zanchetti et al., Circulation 106, 2422 (2002). Review of use in hypertension: P. L. McCormack, A. J. Wagstaff, Drugs 63, 2327-2356 (2003).
Properties: Crystalline solid from ethyl acetate, mp 174-175°.
Melting point: mp 174-175°
Therap-Cat: Antihypertensive.
Keywords: Antihypertensive; Dihydropyridine Derivatives; Calcium Channel Blocker; Dihydropyridine Derivatives.

Others monographs:
SomatotropinFranciumStreptovaricinFlavoxanthin
α-PeltatinN,N-1-Trimethyl-3,3-diphenylpropylamineMethyl IodideBarium Platinous Cyanide
ActinorhodinePsoralidinω-BromoacetophenoneRutinose
Ethyl α-ChloropropionateWilkinson's CatalystMethyl AbietateMethionic Acid
©2016 DrugLead US FDA&EMEA